HGEN HGEN

Humanigen Stock Price

0.3748
0.0037 (1.0%)
Upgrade to Real-Time
Afterhours (Closed)
0.3748
Volume 10,210,364
Bid Price 0.3682
Ask Price 0.377
News (3)
Day High 0.3857

Low
0.35

52 Week Range

High
18.22

Day Low 0.3658
Company Name Stock Ticker Symbol Market Type
Humanigen Inc HGEN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0037 1.0% 0.3748 20:00:00
Open Price Low Price High Price Close Price Prev Close
0.371 0.3658 0.3857 0.363 0.3711
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
14,315 10,210,364 $ 0.3749393 $ 3,828,267 - 0.35 - 18.22
Last Trade Time Type Quantity Stock Price Currency
19:49:33 1 $ 0.3788 USD

Period:

Draw Mode:

Humanigen Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 26.47M 70.63M 59.27M $ 3.60M $ - -4.05 -0.10
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 4.32M 0.80%

more financials information »

Humanigen News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical HGEN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.37020.41150.350.375273610,702,5670.00461.24%
1 Month0.500.570.350.414200113,790,490-0.1252-25.04%
3 Months2.263.250.350.75579918,400,734-1.89-83.42%
6 Months1.854.1050.351.084,676,202-1.48-79.74%
1 Year16.9418.220.352.783,414,031-16.57-97.79%
3 Years10.8529.200.357.122,503,084-10.48-96.55%
5 Years10.8529.200.357.122,503,084-10.48-96.55%

Humanigen Description

Humanigen Inc is a biopharmaceutical company engaged in the development of proprietary monoclonal antibodies for various oncology indications and to enhance T-cell therapies, making these treatments safer and cost-effective. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005.


Your Recent History
NASDAQ
HGEN
Humanigen
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now